(January, 2026) Researchers at the University of Miami Miller School of Medicine, led by Robert W. Keane, Ph.D., and Juan Pablo de Rivero Vaccari, Ph.D., are studying the ways neuronal inflammasomes help the brain respond to stress, infection or injury. Their new review in Trends in Immunology explains how these structures protect the brain, but also how they can cause harm when they become overactive.
“Historically, neurons have been considered immunologically inert cells,” said Dr. Keane, a professor of physiology and biophysics at the Miller School. “However, it is now clear that neurons have an innate immune capacity that plays a critical role in normal brain health, defense and repair. Understanding the roles of neuronal inflammasomes provides new insights into neuroimmune crosstalk and identifies potential targets for modulating repair and inflammation in central nervous system injury and disease.”
What are Neuronal Inflammasomes?
Inflammasomes are protein complexes found inside many cells, including neurons. They sense danger signals such as injury to brain tissue, infection, abnormal proteins associated with diseases like Alzheimer’s disease or Parkinson’s disease or shifts in ions like potassium or calcium that signal cell stress.
When activated, inflammasomes trigger caspase‑1, an enzyme that helps produce inflammatory molecules such as IL‑1β and IL‑18. At balanced levels, this process supports normal brain function. But when neuronal inflammasomes become overactive, inflammation can spread and worsen disease or injury.
Dr. Keane’s and Dr. de Rivero Vaccari’s review brings together evidence from human samples (including cerebrospinal fluid from patients with brain injuries), pre-clinical models of traumatic brain injury, stroke, Alzheimer’s disease and spinal cord injury, and cell‑culture experiments that show how neurons respond to stress.
Across these studies, one sensor, NLRP1, emerged as a major inflammasome in neurons. The researchers explored:
- How NLRP1 becomes activated
- How it interacts with ion channels and stress signals
- How it contributes to inflammation and cell death
- How it may be targeted with medications
“The NLRP1 inflammasome plays an important role in a broad spectrum of central nervous systems diseases and conditions,” Dr. Keane said. “However, it is now evident that NLRP1 is involved in synaptic plasticity. Pharmacological therapeutic modulation of NLRP1 shows promise for maintaining normal brain health and treating injury and disease in the central nervous system.”
Key Findings
At low levels, inflammasomes support healthy processes like:
- Synaptic plasticity (the brain’s ability to learn)
- Axon remodeling (repairing nerve fibers)
- Communication between neurons using exosomes
But when inflammasomes activate too strongly, they can cause neuroinflammation, worsening conditions such as traumatic brain injury, stroke, Alzheimer’s disease and Parkinson’s disease.
Additionally, neurons are not passive. They use sensory proteins to detect stress signals in the brain. These signals can include high levels of ATP outside the cell, acidic conditions, toxic protein buildup and disturbed potassium levels. These conditions can activate inflammasomes, sometimes pushing neurons into pyroptosis, an inflammatory form of cell death.
Several ion channels help regulate inflammasome activity:
- P2X4 and P2X7 receptors react to ATP and promote potassium efflux
- PANX1 channels open during stress and help activate caspase‑1
- ASICs respond to acidic environments
- BK channels help regulate potassium and neuronal firing
These channels interact to regulate neuronal homeostasis but can push the inflammasome into a harmful state when external stimuli are increased.
Inflammasome components, especially ASC specks, can bind to toxic proteins such as amyloid‑β, phosphorylated tau and α‑synuclein. This means inflammasomes may help spread these proteins throughout the brain, worsening diseases like Alzheimer’s and Parkinson’s.
“Accumulation of misfolded or aggregated proteins is a hallmark of neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis,” Dr. Keane said. “ASC interacts with these misfolded aggregated proteins and in some cases increases the toxicity of the misfolded protein. Understanding the ASC interactions with protein aggregates in neurological disease will help to prevent neurotoxicity and improve neuronal survival.”
Implications for Patient Care
Researchers are developing therapies that can lock inflammasome sensors like NLRP1 or NLRP3, prevent ASC specks from forming, stop caspase‑1 from activating and regulate ion channel activity.
Some of these treatments have already shown promise in pre-clinical models of stroke, traumatic brain injury and neurodegeneration. Inflammasome proteins such as ASC, caspase‑1 and NLRP1 can be found in cerebrospinal fluid and blood after brain injuries. These biomarkers could help physicians predict recovery, identify patients at higher risk of complications and personalize treatment plans.
By targeting inflammasomes directly, future therapies may reduce inflammation after brain injury, protect neurons from cell death and slow the progression of neurodegenerative diseases.
“Currently there are no FDA-approved drugs for the treatment of neurodegenerative disease and central nervous system injury,” Dr. Keane said. “Ultimately, targeting neuronal inflammasomes offers promising avenues for treating neurological diseases and injuries by enhancing the brain’s intrinsic healing capacity for repair.”
By: Chad Hanson